Avio Smart Market Stack Limited (ASMS), formerly known as Bartronics India Limited, has entered into a Share Subscription-cum-Shareholders’ Agreement with Hyderabad-based Huwel Lifesciences, following the Memorandum of Understanding signed between the two companies in September 2025.

Under the agreement, ASMS will acquire a minority stake in Huwel Lifesciences and work jointly on business development and project execution initiatives. As part of the arrangement, ASMS will be entitled to a predefined share of net project revenues generated from orders secured through its institutional outreach and business development efforts.

Huwel Lifesciences’ tuberculosis diagnostic platform recently underwent a Health Technology Assessment (HTA) by the Department of Health Research under the Ministry of Health & Family Welfare. The evaluation reviewed molecular TB diagnostic systems deployed across the country.

According to the findings, Huwel’s Quantiplus® MTB FAST platform enables testing at an approximate cost of Rs 340 per sample, significantly lower than the Rs 700–1,000 per test typically incurred under existing government molecular testing programmes. A key advantage of the Quantiplus platform is its compatibility with open RT-PCR systems, allowing authorities to utilise the large network of RT-PCR machines installed during the COVID-19 pandemic, without requiring proprietary hardware or major additional capital investment.

India conducts nearly one crore tuberculosis tests annually under the National TB Elimination Programme (NTEP). With molecular detection and drug-resistance testing combined, the annual molecular TB diagnostics market is estimated at around Rs 1,000 crore. The HTA findings potentially position Huwel’s Quantiplus platform strongly within the public molecular TB diagnostics segment.

Following the assessment, central and state procurement bodies may evaluate the platform for broader adoption under the NTEP.

Commenting on the development, Managing Director Vidhyasagar Reddy said the HTA validation supports cost-effective molecular testing within a nationally significant health programme. He added that the collaboration aligns ASMS with scalable public health solutions while expanding its footprint in the life sciences sector.

The company indicated that this partnership marks the beginning of its broader entry into healthcare and diagnostics-related opportunities.